Charles Matthew Rowland

US Patent:

7695916, Apr 13, 2010

Filed:

Mar 21, 2008

Appl. No.:

12/077935

Inventors:

Olga Iakoubova - San Ramon CA, US
James Devlin - Lafayette CA, US
Charles Rowland - San Leandro CA, US
Carmen Tong - Dublin CA, US

Assignee:

Celera Corporation - Alameda CA

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 911, 435 912

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

US Patent:

8148070, Apr 3, 2012

Filed:

Sep 29, 2009

Appl. No.:

12/569475

Inventors:

Olga Iakoubova - San Ramon CA, US
James J. Devlin - Lafayette CA, US
Carmen Tong - Dublin CA, US
Charles Rowland - San Leandro CA, US

Assignee:

Celera Corporation - Alameda CA

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 61, 435 611, 435 612

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

US Patent:

8557525, Oct 15, 2013

Filed:

Feb 27, 2012

Appl. No.:

13/406221

Inventors:

Alice Wang - Lafayette CA, US
Robert J. Lagier - San Leandro CA, US
Charles M. Rowland - San Francisco CA, US

Assignee:

Celera Corporation - Alameda CA

International Classification:

C12Q 1/68

US Classification:

435 614, 435 912, 435194, 536 243, 536 2433

Abstract:

The present invention relates to a composite metastasis score (“cMS”) based on expression of a 14-gene molecular signature (referred to as a metastasis score, or “MS”) in combination with progesterone receptor (PR) expression that is useful for predicting breast cancer metastasis. In preferred embodiments, the cMS is determined by applying weighted coefficients to MS and PR. The present invention provides methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information for predicting risk of breast cancer metastasis, among other embodiments.

US Patent:

20130058914, Mar 7, 2013

Filed:

Feb 28, 2012

Appl. No.:

13/407501

Inventors:

Olga IAKOUBOVA - San Ramon CA, US
James DEVLIN - Lafayette CA, US
Charles ROWLAND - San Leandro CA, US
Carmen TONG - Dublin CA, US

Assignee:

CELERA CORPORATION - ALAMEDA CA

International Classification:

C12Q 1/68
A61K 31/7088
A61K 38/02
A61K 39/395

US Classification:

4241301, 435 611, 514 44 A, 514 11

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

US Patent:

20140072550, Mar 13, 2014

Filed:

Jun 27, 2013

Appl. No.:

13/929136

Inventors:

James J. DEVLIN - Lafayette CA, US
Carmen TONG - Dublin CA, US
Charles ROWLAND - San Leandro CA, US

Assignee:

CELERA CORPORATION - Alameda CA

International Classification:

C12Q 1/68

US Classification:

4241301, 435 611, 514423, 514548

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

US Patent:

20200123610, Apr 23, 2020

Filed:

Aug 28, 2019

Appl. No.:

16/553592

Inventors:

- San Juan Capistrano CA, US
James J. DEVLIN - Lafayette CA, US
Carmen TONG - Dublin CA, US
Charles ROWLAND - San Leandro CA, US

International Classification:

C12Q 1/6883
G01N 33/68

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

US Patent:

20170022563, Jan 26, 2017

Filed:

May 10, 2016

Appl. No.:

15/150636

Inventors:

- San Clemente CA, US
James J. DEVLIN - Lafayette CA, US
Carmen TONG - Dublin CA, US
Charles ROWLAND - San Leandro CA, US

International Classification:

C12Q 1/68
G01N 33/68

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.